Clinical Trial Update: Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib [Phase 2]

View source ↗

Summary

Phase 2 study of XL647 in non-small cell lung cancer patients who progressed after initial response to gefitinib or erlotinib has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• XL647

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED